Last reviewed · How we verify
GSK618334
At a glance
| Generic name | GSK618334 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334 (PHASE1)
- An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand (PHASE1)
- GSK618334 Repeat Dose Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK618334 CI brief — competitive landscape report
- GSK618334 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI